David E. Shaw

基本信息

Career Trajectory

Bio

Research Use of very long molecular dynamics simulations to study the structural changes in proteins associated with protein folding, protein-ligand binding, molecular signaling, ion transport, and other biologically significant processes.

Research Interests

Papers共 473 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Design of antigens to present a tumor-specific cryptic epitope

Huafeng Xu,Timothy Palpant, Qi Wang,David E. Shaw

biorxiv（2024）

Cited0Views0Bibtex

Figure S3 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia

openalex（2024）

Cited0Views0Bibtex

Discovery of Lirafugratinib (RLY-4008), a Highly Selective Irreversible Small-Molecule Inhibitor of FGFR2

Proceedings of the National Academy of Sciencesno. 6 (2024)

Cited5Views0WOSBibtex

Figure S5 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia

openalex（2024）

Cited0Views0Bibtex

Figure S7 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia

openalex

Cited0Views0Bibtex

Table S2 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia

openalex

Cited0Views0Bibtex

Supplemental Text from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia

openalex

Cited0Views0Bibtex

Figure S2 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia

crossref（2024）

Cited0Views0Bibtex

Figure S1 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia

openalex（2024）

Cited0Views0Bibtex

Figure S4 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia

openalex

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn

Professor

Papers共 473 篇Author StatisticsCo-AuthorSimilar Experts